Breaking News

Samsung Biologics Launches High-Concentration Formulation Platform

Designed to identify unintended pH changes, enhance formulation stability, and reduce viscosity to ensure efficacy and maximize drug delivery.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Samsung Biologics, a global CDMO, launched a new high-concentration formulation platform to support the development and manufacturing of high-dose biopharmaceuticals.   S-HiCon is designed to proactively identify unintended pH changes, enhance formulation stability, and reduce viscosity to ensure efficacy and maximize drug delivery. Through optimization of pH, buffer species, and excipients, along with a preliminary ‘Concentration Gate Check’ process, the platform tests formulation...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters